Abstract
Objective:
To identify methylated genes in serum with diagnostic potentials for early colorectal cancer (CRC).
Methods:
Serum methylation levels of up to 12 genes were measured in two sets of serum samples with the second set from 26 stage I CRC patients and 26 age/gender-matched controls.
Results:
Serum methylation levels of TAC1, SEPT9, and EYA4 were significant discriminants between stage I CRC and healthy controls. Combination of TAC1 and SEPT9 rendered 73.1% sensitivity with 92.3% specificity.
Conclusion:
Serum methylation levels of TAC1. SEPT9 and EYA4 may be useful biomarkers for early detection of CRC though a validation study is necessary.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Area Under Curve
-
Biomarkers, Tumor / blood*
-
Biomarkers, Tumor / genetics
-
Case-Control Studies
-
Colorectal Neoplasms / blood*
-
Colorectal Neoplasms / diagnosis
-
Colorectal Neoplasms / genetics
-
DNA Methylation
-
Early Detection of Cancer
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Pilot Projects
-
Prospective Studies
-
ROC Curve
-
Septins / blood*
-
Septins / genetics
-
Trans-Activators / blood*
-
Trans-Activators / genetics
-
Transmembrane Activator and CAML Interactor Protein / blood*
-
Transmembrane Activator and CAML Interactor Protein / genetics
Substances
-
Biomarkers, Tumor
-
EYA4 protein, human
-
TNFRSF13B protein, human
-
Trans-Activators
-
Transmembrane Activator and CAML Interactor Protein
-
SEPTIN9 protein, human
-
Septins